通过调控肠道微生物群增强免疫检查点阻断疗法的临床覆盖范围和抗癌疗效。
Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.
作者信息
Pitt Jonathan M, Vétizou Marie, Gomperts Boneca Ivo, Lepage Patricia, Chamaillard Mathias, Zitvogel Laurence
机构信息
Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM Unit U1015, Villejuif, France; Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France.
Institut Pasteur, Unit of Biology and Genetics of the Bacterial Cell Wall, Paris, France; INSERM, Equipe Avenir, Paris, France.
出版信息
Oncoimmunology. 2016 Feb 18;6(1):e1132137. doi: 10.1080/2162402X.2015.1132137. eCollection 2017.
Abstract
Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct species of the gut microbiota, signifying novel approaches to improve such immunotherapies.
摘要
尽管免疫检查点阻断剂的抗癌治疗取得了前所未有的成功，但它在大多数患者中无法控制肿瘤形成，并且常常引发免疫相关不良事件（irAE）。我们最近的研究表明，CTLA-4阻断的免疫刺激和抗肿瘤作用取决于肠道微生物群的不同种类，这意味着有新的方法来改进此类免疫疗法。
相似文献
1
Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.通过调控肠道微生物群增强免疫检查点阻断疗法的临床覆盖范围和抗癌疗效。
Oncoimmunology. 2016 Feb 18;6(1):e1132137. doi: 10.1080/2162402X.2015.1132137. eCollection 2017.
2
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
3
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.免疫检查点抑制剂相关不良事件的免疫发病机制：肠道微生物组和 Th17 细胞的作用。
Front Immunol. 2019 Sep 26;10:2254. doi: 10.3389/fimmu.2019.02254. eCollection 2019.
4
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
5
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
6
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.癌症免疫检查点阻断的耐药机制：肿瘤内在和外在因素。
Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001.
7
Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events.跟随肠道菌群：肠道微生物群在预测和治疗免疫相关不良事件中的新兴作用。
Curr Opin Oncol. 2023 Jul 1;35(4):248-253. doi: 10.1097/CCO.0000000000000957. Epub 2023 May 11.
8
Molecular Events Behind Adverse Effects.不良作用背后的分子事件。
Adv Exp Med Biol. 2020;1248:119-141. doi: 10.1007/978-981-15-3266-5_6.
9
Modulation of the Gut Microbiota Alters the Tumour-Suppressive Efficacy of Tim-3 Pathway Blockade in a Bacterial Species- and Host Factor-Dependent Manner.肠道微生物群的调节以细菌种类和宿主因子依赖的方式改变Tim-3通路阻断的肿瘤抑制功效。
Microorganisms. 2020 Sep 11;8(9):1395. doi: 10.3390/microorganisms8091395.
10
Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade?肠道微生物能预测联合免疫检查点阻断疗法的疗效和毒性吗？
Cancer Cell. 2021 Oct 11;39(10):1314-1316. doi: 10.1016/j.ccell.2021.09.013.
引用本文的文献
1
Gut microbiome versus thyroid cancer: Association and clinical implications (Review).肠道微生物群与甲状腺癌：关联及临床意义（综述）
Oncol Lett. 2025 May 27;30(1):368. doi: 10.3892/ol.2025.15114. eCollection 2025 Jul.
2
Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification.肝细胞癌免疫治疗中的肠道微生物群：免疫微环境重塑与肠道微生物群修饰
Gut Microbes. 2025 Dec;17(1):2486519. doi: 10.1080/19490976.2025.2486519. Epub 2025 Apr 1.
3
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.肠道微生物群作为抗癌治疗的新靶点：从作用机制到调控手段
NPJ Biofilms Microbiomes. 2025 Mar 11;11(1):43. doi: 10.1038/s41522-025-00678-x.
4
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.实体瘤中肠道微生物群与免疫检查点抑制剂之间关系的见解
Cancers (Basel). 2024 Dec 23;16(24):4271. doi: 10.3390/cancers16244271.
5
Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review.评估免疫检查点抑制剂及联合疗法在脑转移瘤治疗中的安全性：一项全面综述
Cancers (Basel). 2024 Nov 23;16(23):3929. doi: 10.3390/cancers16233929.
6
The FITNESS study: longitudinal geriatric assessment, treatment toxicity, and biospecimen collection to assess functional disability among older adults with lung cancer.FITNESS研究：纵向老年评估、治疗毒性及生物样本采集，以评估老年肺癌患者的功能残疾情况
Front Aging. 2024 Jun 7;5:1268232. doi: 10.3389/fragi.2024.1268232. eCollection 2024.
7
Critical role of the gut microbiota in immune responses and cancer immunotherapy.肠道微生物群在免疫反应和癌症免疫治疗中的关键作用。
J Hematol Oncol. 2024 May 14;17(1):33. doi: 10.1186/s13045-024-01541-w.
8
synergize with oxaliplatin to reduce tumor burden in mice with lung adenocarcinoma.与奥沙利铂协同作用，降低肺癌小鼠的肿瘤负担。
mSystems. 2024 Apr 16;9(4):e0132323. doi: 10.1128/msystems.01323-23. Epub 2024 Mar 14.
9
The Use of Fecal Microbiota Transplant in Overcoming and Modulating Resistance to Anti-PD-1 Therapy in Patients with Skin Cancer.粪便微生物群移植在克服和调节皮肤癌患者抗PD-1治疗耐药性中的应用
Cancers (Basel). 2024 Jan 24;16(3):499. doi: 10.3390/cancers16030499.
10
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices.晚期非小细胞肺癌免疫治疗的进展：优化治疗顺序并确定最佳选择
Cancers (Basel). 2023 Sep 13;15(18):4547. doi: 10.3390/cancers15184547.
本文引用的文献
1
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
2
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.共生双歧杆菌可促进抗肿瘤免疫并增强抗程序性死亡受体配体1（PD-L1）的疗效。
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.
3
Cancer and the gut microbiota: an unexpected link.癌症与肠道微生物群：一个意想不到的联系。
Sci Transl Med. 2015 Jan 21;7(271):271ps1. doi: 10.1126/scitranslmed.3010473.
4
Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms.浆细胞样树突状细胞通过先天和适应性机制介导对肠道共生分子的抗炎反应。
Cell Host Microbe. 2014 Apr 9;15(4):413-23. doi: 10.1016/j.chom.2014.03.006.
5
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.肠道微生物群调节环磷酰胺的抗癌免疫作用。
Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.
6
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.共生菌通过调节肿瘤微环境来控制癌症对治疗的反应。
Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527.
7
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
8
A new vision of immunity: homeostasis of the superorganism.一种新的免疫观：超有机体的内稳态。
Mucosal Immunol. 2010 Sep;3(5):450-60. doi: 10.1038/mi.2010.20. Epub 2010 May 5.
9
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.细胞毒性T淋巴细胞相关抗原4抗体阻断后癌症患者的小肠结肠炎
J Clin Oncol. 2006 May 20;24(15):2283-9. doi: 10.1200/JCO.2005.04.5716.
Zotero 插件